- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02757755
Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults
Study Overview
Status
Conditions
Detailed Description
AB-SA01 consists of three bacteriophages (viruses) that target Staphylococcus aureus bacteria.
The safety of AB-SA01 will be assessed when topically administered once daily to the volar aspect of the forearm at a dose of 10^8 plaque forming units (PFU) per phage for 3 consecutive days, and then at a dose of 10^9 plaque forming units (PFU) per phage for 3 consecutive days. Both AB-SA01 and placebo will be administered to each subject to provide his/her own control for evaluation of skin reactions. The right or left placement of the placebo will be randomized and double-blinded.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Silver Spring, Maryland, United States, 20910
- Clinical Trials Center, WRAIR
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, 18 to 60 years of age, inclusive, at the time of the first treatment
- Willing and able to sign the informed consent and adhere to the study schedule
- Healthy subject as determined by the principal investigator or designee via medical history and clinical examination before enrollment in the study
- Normal skin of the volar aspect of the forearms, as determined by the principal investigator or designee via examination
- If female, the subject is not pregnant or breastfeeding and has a negative urine pregnancy test at screening, and prior to receiving the first study treatment
- If female of childbearing potential, the subject agrees to use adequate contraception from screening, throughout the study period, and for 30 days after completion of treatment.
- If male, subjects with female partners of childbearing potential must agree to use adequate contraception from screening, throughout the study period, and for 30 days after completion of treatment
Exclusion Criteria:
- Any past use of a bacteriophage product, or planned use from the time of screening and during the entire study period
- Planned participation in another clinical trial and/or use of any product that is investigational, drug, biologic or device, within 30 days preceding screening and during the entire study period
- Skin lesions, chronic skin conditions, scars or tattoo placement, as established by skin examination before enrollment in the study that would interfere with study treatment.
- Chronic administration (defined as more than 14 days total in the past 6 months) of immunosuppressant or other immune-modifying drugs within 6 months prior to the first study treatment
- Chronic administration of topical steroids to the volar aspect of the forearms (defined as more than 14 days total in the 6 months prior to the first study treatment)
- Any other prohibited medication or treatment
- Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history, physical examination, and screening serology (HIV, HbsAg, and anti-HCV)
- History of congenital or hereditary immunodeficiency
- History of any severe allergic reaction or hypersensitivity (anaphylaxis)
- History of allergic reaction or irritant contact dermatitis due to wound dressings (eg, adhesive tapes, bandages, gauze)
- History of allergic reaction to castor oil
- Acute disease and/or fever at the time of study treatment
- Acute or chronic, clinically significant pulmonary, cardiovascular, neurologic, hepatic, or renal functional abnormality as determined by medical history, physical examination, or laboratory screening tests
- Screening lab results with any Grade 2 or higher abnormality or clinically significant Grade 1 abnormality, as determined by the Common Terminology Criteria for Adverse Events (CTCAE).
- Administration of immunoglobulins and/or any blood products within the 3 months preceding the first study treatment or planned administration during the study period
- Recent (within 12 months prior to screening) history of chronic alcohol abuse, defined as a history of ethanol consumption on average > 40 g/day for women and 60 g/day for men for at least 12 months prior to Baseline.
- Recent (within 12 months prior to screening) history of illicit drug abuse
- Inability to comply with study requirements and restrictions
- Any reason, considered by the principal investigator or designee, to preclude subject involvement in the study
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 10^8
AB-SA01 (10^8) and Placebo
|
Gauze pads will be saturated with AB-SA01 and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days.
Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
Gauze pads will be saturated with Placebo and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days.
Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
|
Experimental: Cohort 10^9
AB-SA01 (10^9) and Placebo
|
Gauze pads will be saturated with AB-SA01 and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days.
Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
Gauze pads will be saturated with Placebo and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days.
Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events
Time Frame: From first dose through the End of Study visit (Day 14 ± 2 days)
|
Occurrence, intensity, and relationship of adverse events (AEs) from first dose through the End of Study visit
|
From first dose through the End of Study visit (Day 14 ± 2 days)
|
Change from Baseline in Clinical Laboratory Tests
Time Frame: Day 0 (pre-dose), Day 3, and Day 14 ± 2 days
|
Clinical laboratory tests (hematology, chemistry, and urinalysis)
|
Day 0 (pre-dose), Day 3, and Day 14 ± 2 days
|
Skin Reaction Change from Baseline
Time Frame: Days 0, 1, and 2 (pre- and post-dose), and on Day 3, Day 7 ± 1 day, and Day 14 ± 2 days
|
skin reaction assessments
|
Days 0, 1, and 2 (pre- and post-dose), and on Day 3, Day 7 ± 1 day, and Day 14 ± 2 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jeffrey Livezey, MD, Walter Reed Army Institute of Research (WRAIR)
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- AB-SA01-01
- WRAIR-2285 (Other Identifier: Walter Reed Army Institute of Research)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on AB-SA01 (10^8 PFU per phage)
-
North Idaho DermatologyCompletedVerruca VulgarisUnited States
-
Jonathan StineGrifols Therapeutics LLCWithdrawnCirrhosis, Liver | Portal Vein ThrombosisUnited States
-
University of OxfordNational Institute for Health Research, United Kingdom; The PATH Malaria Vaccine...CompletedPlasmodium Falciparum MalariaUnited Kingdom
-
Yuzuncu Yıl UniversityCompletedOveractive Bladder | Obstructive Sleep Apnea | Overactive Bladder SyndromeTurkey
-
SymyooCompleted
-
Seoul National University HospitalCompletedNocturiaKorea, Republic of
-
Corporacion Parc TauliCompletedDiabetic Neuropathy | Diabetic Nerve Problems | Diabetic Complications NeurologicalPakistan
-
Kenya Medical Research InstituteFoundation for Innovative New Diagnostics (FIND)Unknown
-
University of Michigan Rogel Cancer CenterRush University Medical CenterCompletedPancreatic CancerUnited States